A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors
Status:
Terminated
Trial end date:
2019-07-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and efficacy of OMP-336B11. OMP-336B11 is an
engineered human protein that was designed to bind to the GITR receptor on T cells and
activate the immune system to recognize and eliminate cancer cells.